CMS Open Payments · Program Year 2024
Cascination AG
Cascination AG reported $694.27 across General Payments, Research, and Ownership to 22 physicians and teaching hospitals across 22 transactions.
- $694.27
- All-tracks total
- 22
- Transactions
- 22
- Recipients
- #1864
- of 1,925 companies
Cascination AG reported $694.27 across all CMS Open Payments tracks (General + Research + Ownership) to 22 physicians and teaching hospitals in Program Year 2024 - ranking #1864 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $694.27, averaging $31.56 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer cascination-ag Cascination AG
$694.27 · #1864/1,925 · 0.0% industry · PY2024
- TOT $694.27
- RANK #1864
- SHARE 0.0%
- TXN 22
- RCP 22
- CAT 1
- GEN $694.27
- TOP1 5.6%
- PY 2024
Volume peers
Nearest volume peer: Oculotix, Inc. ($700.00)
Cascination AG sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Cascination AG
Rank #1864 of 1,925 companies in CMS Open Payments for 2024 belongs to Cascination AG, which reported $694.27 across 22 transactions to 22 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $31.56 per transaction and $31.56 per recipient.
Of the 1 general-payment categories charted below, "Food and Beverage" is the largest at $694.27 across 22 transactions, 100.0% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Food and Beverage" leads Cascination AG's 1-category general-payment breakdown at $694.27, 100.0% of the reported total.
How Cascination AG divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $694.27 | 22 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $193.90 (27.9%) of $694.27 in this company's General Payments records across 22 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Cascination AG
The five named recipients with the highest reported General Payments from this company
- 1
Govindarajan Narayanan
$38.78 across 1 reported transactions
- 2
Brian Schiro
$38.78 across 1 reported transactions
- 3
Barry Katzen
$38.78 across 1 reported transactions
- 4
Andrew Niekamp
$38.78 across 1 reported transactions
- 5
Ripal Gandhi
$38.78 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Cascination AG's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Cascination AG.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Cascination AG.
Showing 6 of 1,924 companies with CMS-reported payment data.
Movair Inc
United Medical Systems (DE), Inc.
Atrility Medical, Inc.
Sechrist Industries Inc
Elekta AB (publ)
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.